CN101966191A - Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure - Google Patents
Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure Download PDFInfo
- Publication number
- CN101966191A CN101966191A CN 201010234038 CN201010234038A CN101966191A CN 101966191 A CN101966191 A CN 101966191A CN 201010234038 CN201010234038 CN 201010234038 CN 201010234038 A CN201010234038 A CN 201010234038A CN 101966191 A CN101966191 A CN 101966191A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- telmisartan
- blood pressure
- compound preparation
- pharmaceutical salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an amlodipine- and telmisartan-containing compound preparation for curing high blood pressure, which comprises the following components: main ingredients including amlodipine or pharmaceutical salt thereof, hydrochlorothiazide and telmisartan or pharmaceutical salt thereof, and a medicinal carrier, wherein in each preparation unit, if based on the amlodipine, the amlodipine or the amlodipine pharmaceutical salt accounts for 2.5 to 10.0mg, and if based on the telmisartan, the telmisartan or the pharmaceutical salt thereof accounts for 10.0 to 80.0mg and the hydrochlorothiazide accounts for 6.25 to 25.0mg. The compound has the advantages that: base on a mechanism that the complementary effects of the medicaments can be fully played by using the medicaments in combination, the curing effect is increased, standards are reached quickly, the standard rate of the blood pressure reaches 80 percent, unexpected effects related to the increase of certain medicament are reduced, and the action can be kept for a long time. The compound preparation of the invention has the characteristics of quick response, high rate of standard blood pressure, small side effects and low cost.
Description
Technical field:
The present invention relates to a kind of compound preparation that hypertension contains amlodipine and telmisartan for the treatment of, belong to drug world.
Background technology:
Along with China's rapid growth of economy, the drastic change of people life style, the acceleration of urbanization, aging, the cardiovascular diseases has become first or second cause of the death of rural and urban population.Especially patients with hypertension, its sickness rate accounts for total population about 15%.Morbidity colony is so big, seeks medicine evident in efficacy, that side effect is little and seems more important.
The hypertensive medicine of treatment has multiple at present, such as calcium antagonist (CCBs), converting enzyme inhibitor (ACEI), angiotensin ii receptor antagonist (ARBs) etc., but single medicine treatment hypertension is difficult up to standard in a short time, and Most patients need be taken two or more antihypertensive drug can reach the blood pressure lowering target.Especially blood pressure exceeds desired value 20/10mmHg, and beginning need be taken two kinds of medicines often.Single medicine is prone to drug resistance, and because the bigger probability that toxicity occurs of dosage is also bigger.Majority is to give two or more drug administration treatments simultaneously.But several drugs is taken simultaneously, and patient's compliance is poor, and the collocation of the dosage of several drugs is not because the problem of formulation dosage and doctor's the degree of awareness often are optimized proportionings.In recent years, though the depressor of much new good effect few side effects is arranged, the controlling blood pressure compliance rate is relatively low.But drug combination can be used two or more depressor, and the dosage of every kind of medicine is little, and the therapeutical effect of medicine should have collaborative or the effect of addition at least, and its ill effect can be cancelled out each other or not overlapping at least or addition.Medicine kind number used during drug combination is too much unsuitable, and crossing to have complicated drug interaction at most.Therefore, select to merge very difficulty of medication amount and kind, need a large amount of development tests.
Therefore, a kind of new treatment pattern is applied to clinical gradually, and the compound hypertension medicine preparation is internationally recognized a kind of orientation treatment.Because the compound antihypertensive drug prescription is followed the principle that different mechanism of action medicines carry out proportioning usually, therefore show as the advantage that increases curative effect or reduce side effect, obtained better controlling of blood pressure effect.
Summary of the invention:
The object of the present invention is to provide a kind of side effect little, taking convenience can effectively be treated the compound preparation of hypertensive three kinds of antihypertensive drugs, and this compound preparation is controlling blood pressure effectively.
Purpose of the present invention is implemented by following technical scheme: a kind ofly treat the compound preparation that hypertension contains amlodipine and telmisartan, include following composition: amlodipine (amlodipine) or amlodipine officinal salt, hydrochlorothiazide (hydrochlorothiazide), telmisartan (telmisartan) or its officinal salt are Main Ingredients and Appearance, being equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described amlodipine (amlodipine) or amlodipine officinal salt, count 2.5-10.0mg with amlodipine, described telmisartan (telmisartan) or its officinal salt, count 10.0-80.0mg with telmisartan, described hydrochlorothiazide (hydrochlorothiazide) is 6.25-25.0mg.
It is a kind of that to treat the compound preparation that hypertension contains amlodipine and telmisartan be capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Advantage of the present invention: be to give full play to the complementary mechanism of action of medicine according to drug combination to increase curative effect, up to standard fast, make the blood pressure compliance rate reach 80%, reduce with a certain dosage and increase relevant untoward reaction.Compound formulation of the present invention has instant effect, blood pressure compliance rate height, and side effect is little, the characteristics that cost is low.
The specific embodiment:
Further set forth medicine of the present invention by the following examples, these embodiment are only presented for purposes of illustration, do not limit the scope of the invention.
Embodiment 1-4 is listed as follows:
Use the conventional method in the pharmaceuticals industry among the embodiment, the according to the form below formulation becomes tablet, makes the used pharmaceutically suitable carrier of tablet--and adjuvant is the conventional adjuvant of this area.Wherein the proportioning of its Main Ingredients and Appearance is as follows:
Use the conventional method in the pharmaceuticals industry simultaneously among the embodiment, can also be prepared into capsule, soft capsule, granule, powder, controlled release agent or injection dosage form,, pharmaceutically suitable carrier--used adjuvant is the conventional adjuvant of this area of this dosage form.
Embodiment 5: the present invention treats hypertensive compound preparation clinical trial:
Below will be by human body pharmacodynamic experiment explanation pharmaceutical composition of the present invention to hypertensive therapeutical effect.
1, physical data:
Clinical 400 routine hypertension philtrums, age 40--50 year, 140 examples; Age 51--60 year, 140 examples, age 61--70 year, 120 examples.
2, diagnostic criteria: according to " Chinese hypertension prevention and control guide ", hypertension is defined as: do not obey under the antihypertensive situation systolic pressure 〉=140mmHg and/or diastolic pressure 〉=90mmHg.
3, Therapeutic Method:, adopt randomized to be divided into 4 groups, every group of this compound formulation medicine that adopts embodiment of the invention 1-4 gained respectively with 400 routine hypertensive patients, make tablet, every day is once oral, according to the dose difference of tablet, each a slice or two took 6 days.
4, efficacy assessment standard:
Draft according to " Chinese hypertension prevention and control guide ".The target of antihypertensive therapy is blood pressure to be returned to " normally " or " ideal " level.40-60 year patient be depressurized to ideal or normal arterial pressure (≤130/85mmHg), 60-70 year patient be depressurized at least normal high value (≤140/90mmHg).
5, therapeutic outcome: administration begins to carry out respectively in the 1st day, 2 days, 3 days, 4 days, 5 days, 6 days blood pressure determination.The result shows that medication is after 6 days, 4 groups of the embodiment of the invention are totally 400 routine hypertension philtrums, and it is up to standard to amount to 320 routine patient's blood pressures, promptly returns to " normally " or " ideal " level, mean blood pressure compliance rate 80% illustrates that the present embodiment compound medicine has good curing hypertension effect.
Curative effect sees the following form:
| Case load | Blood pressure case sum up to standard | The below standard case sum of blood pressure | The mean blood pressure compliance rate |
| 400 | 320 | 80 | 80％ |
Discuss
This product is the hypertensive compound formulation of treatment, its blood pressure compliance rate higher 80%.
Claims (2)
1. treat the compound preparation that hypertension contains amlodipine and telmisartan for one kind, it is characterized in that, it includes following composition: amlodipine or amlodipine officinal salt, hydrochlorothiazide, telmisartan or its officinal salt be Main Ingredients and Appearance, be equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described amlodipine or amlodipine officinal salt, count 2.5-10.0mg with amlodipine, described telmisartan or its officinal salt, count 10.0-80.0mg with telmisartan, described hydrochlorothiazide is 6.25-25.0mg.
2. a kind of compound preparation that hypertension contains amlodipine and telmisartan for the treatment of according to claim 1 and 2 is characterized in that described compound preparation is capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010234038 CN101966191A (en) | 2009-07-14 | 2010-07-13 | Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910139990.6 | 2009-07-14 | ||
| CN200910139990 | 2009-07-14 | ||
| CN 201010234038 CN101966191A (en) | 2009-07-14 | 2010-07-13 | Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101966191A true CN101966191A (en) | 2011-02-09 |
Family
ID=43545453
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010234038 Pending CN101966191A (en) | 2009-07-14 | 2010-07-13 | Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure |
| CN 201010234027 Pending CN101966187A (en) | 2009-07-14 | 2010-07-13 | Amlodipine- and erbesartan-containing compound preparation for treating hypertension |
| CN 201010234033 Pending CN101966189A (en) | 2009-07-14 | 2010-07-13 | Amlodipine and olmesartan-containing compound preparation for treating hypertension |
| CN 201010233860 Pending CN102038687A (en) | 2009-07-14 | 2010-07-13 | Amlodipine and losartan-containing compound preparation for treating hypertension |
| CN 201010234028 Pending CN101966188A (en) | 2009-07-14 | 2010-07-13 | Amlodipine and candesartan-containing compound preparation for treating hypertension |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010234027 Pending CN101966187A (en) | 2009-07-14 | 2010-07-13 | Amlodipine- and erbesartan-containing compound preparation for treating hypertension |
| CN 201010234033 Pending CN101966189A (en) | 2009-07-14 | 2010-07-13 | Amlodipine and olmesartan-containing compound preparation for treating hypertension |
| CN 201010233860 Pending CN102038687A (en) | 2009-07-14 | 2010-07-13 | Amlodipine and losartan-containing compound preparation for treating hypertension |
| CN 201010234028 Pending CN101966188A (en) | 2009-07-14 | 2010-07-13 | Amlodipine and candesartan-containing compound preparation for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN101966191A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102327272A (en) * | 2011-07-14 | 2012-01-25 | 海南锦瑞制药股份有限公司 | Fully-novel oral solid pharmaceutical composition and preparation method thereof |
| CN110755429A (en) * | 2018-07-26 | 2020-02-07 | 北京市石景山区高血压联盟研究所 | Compound antihypertensive medicine composition, preparation and application thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743381B (en) * | 2011-04-22 | 2014-08-27 | 重庆市力扬医药开发有限公司 | Stable candesartan cilexetil amlodipine pharmaceutical composition and its preparation method |
| CN102342943B (en) * | 2011-07-14 | 2013-07-10 | 海南锦瑞制药股份有限公司 | Brand new oral solid medicinal composition and its preparation method |
| WO2018138578A1 (en) * | 2017-01-25 | 2018-08-02 | The George Institute for Global Health | Compositions for the treatment of hypertension |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
-
2010
- 2010-07-13 CN CN 201010234038 patent/CN101966191A/en active Pending
- 2010-07-13 CN CN 201010234027 patent/CN101966187A/en active Pending
- 2010-07-13 CN CN 201010234033 patent/CN101966189A/en active Pending
- 2010-07-13 CN CN 201010233860 patent/CN102038687A/en active Pending
- 2010-07-13 CN CN 201010234028 patent/CN101966188A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102327272A (en) * | 2011-07-14 | 2012-01-25 | 海南锦瑞制药股份有限公司 | Fully-novel oral solid pharmaceutical composition and preparation method thereof |
| CN102327272B (en) * | 2011-07-14 | 2013-08-14 | 海南锦瑞制药股份有限公司 | Oral solid pharmaceutical composition and preparation method thereof |
| CN110755429A (en) * | 2018-07-26 | 2020-02-07 | 北京市石景山区高血压联盟研究所 | Compound antihypertensive medicine composition, preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101966188A (en) | 2011-02-09 |
| CN101966187A (en) | 2011-02-09 |
| CN102038687A (en) | 2011-05-04 |
| CN101966189A (en) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008486A (en) | Compound preparation containing telmisartan for treating hypertension | |
| CN102008709B (en) | Moexipril-contained compound preparation for treating hypertension | |
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| CN101966191A (en) | Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| CN110325214A (en) | Low-dose drugs for preventing and treating neure damage combine | |
| CN101954082A (en) | Angiotensin-converting enzyme inhibitor-containing compound preparation for treating hypertension | |
| CN113648380A (en) | Composition for treating diabetes | |
| CN102283834B (en) | Orlisat-containing medicinal composition and application thereof | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN101269064A (en) | Application of myricetin in medicament for treating prostate gland disease | |
| CN101579342A (en) | Desloratadine-contained patulin composition | |
| CN101940619A (en) | Chinese medicinal preparation for treating guillain-barre syndrome (GBS) diseases and preparation method thereof | |
| CN106265674A (en) | Tetramethyluric acid prevention and the application for the treatment of diabetes | |
| CN101125143A (en) | Hypertension-treating compound medicine | |
| CN113616651B (en) | Compound antihypertensive pharmaceutical composition and application thereof | |
| CN117243947A (en) | Application of daphnetin and combination containing daphnetin in preparation of diabetes complication medicaments | |
| CN102743361A (en) | Irbesartan hydrochlorothiazide capsule | |
| CN115778945A (en) | Composition and application thereof in preparing medicine for treating neuropathic pain | |
| CN101623294B (en) | Composition for reducing blood pressure | |
| CN103432596A (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| CN107648226A (en) | A kind of pharmaceutical composition for treating antimigraine and preparation method thereof | |
| CN107773692A (en) | A kind of medical composition and its use for being used to reduce blood pressure and blood lipoid | |
| CN104940206A (en) | Medicine composition containing miglitol and application thereof in prevention and treatment of diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110209 |